, Volume 93, Issue 4, pp 502–506 | Cite as

Effects in the X-maze anxiety model of agents acting at 5-HT1 and 5-HT2 receptors

  • M. A. E. Critchley
  • S. L. Handley
Original Investigations


Three 5-HT agonists produced a dose-related fall in open/total arm entry ratio in the elevated X-maze model of anxiety at doses which did not affect total entries. The relative potency, 8-hydroxy-2-(di-n-propylamino)tetra lin (8-OH-DPAT)≫5-methoxy-N,N-dimethyltryptamine (5-MeODMT)>=5-methoxy-3(tetrahydropyridin-4-yl)1H-indole (RU 24969), was unrelated to the occurrence of wet dog shakes and suggests that 5-HT1 rather than 5-HT2 receptors may be involved. However, the 5-HT2 receptor antagonists ritanserin, ketanserin and seganserin caused an anxiolytic-like increase in entry ratio, although only ritanserin produced this effect across the dose range tested. +/-Pindolol, an antagonist at 5-HT1 receptors, showed a biphasic dose-response curve with a fall in entry ratio at one high dose. The effect of a submaximal dose of 8-OH-DPAT was prevented by pindolol but not by a similarly anxiolytic dose of ritanserin or diazepam. A higher dose of diazepam caused intense muscle hypotonia in combination with 8-OH-DPAT. Since open/total entry ratio appears to represent choice, rather than suppression or delay, of a response, the effects seen may indicate involvement of 5-HT receptors in anxiety separately from any change in the ability to withhold a response. The precise role of each receptor subtype, however, remains to be determined.

Key words

X-maze Anxiety 5-HT ligands 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Arriaga F, Leitas J, Mills FJ, Padua J, Ruiz I, Tropa J, Sousa MP (1984) R55667, an effective non-benzodiazepine anxiolytic. Proc. 14th C.I.N.P. Congr Florence [Abstr] P726Google Scholar
  2. Bradley PB, Engel G, Fenuik W, Fozard JR, Humphrey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-HT. Neuropharmacology 25:563–576Google Scholar
  3. Ceulemans D, Hoppenbrouwers ML, Gelders Y, Reyntjens A (1984) Serotonin blockade or benzodiazepines: What kind of anxiolysis? Proc 14th C.I.N.P. Congr Florence [Abstr] P726Google Scholar
  4. Colpaert FC, Meet TF, Niemegeers CJE, Janssen PAJ (1985) Behavioural and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in the rat. Psychopharmacology 86:45–54Google Scholar
  5. Dourish CT, Hutson PH, Curzon G (1985) Low doses of the putative serotonin agonist 8-hydroxy-2(di-n-propylamino)tetralin (8-OH-DPAT) elicit feeding in the rat. Psychopharmacology 86:197–204Google Scholar
  6. Engel JA, Hjorth S, Svensson K, Carlsson A, Liljequist B (1984) Anticonflict effects of the putative serotonin receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). Eur J Pharmacol 105:365–368Google Scholar
  7. File SE, Johnston AL, Pellow S (1987) Effects of compounds acting at CNS 5-hydroxytryptamine systems on anxiety in the rat. Br J Pharmacol 90:265PGoogle Scholar
  8. Gardner CR (1985) Pharmacological studies of the role of serotonin in animal models of anxiety. In: Green AR (ed) Neuropharmacology of serotonin. Oxford University Press, New YorkGoogle Scholar
  9. Gardner CR (1986) Recent developments in 5-HT-related pharmacology of animal models of anxiety. Pharmacol Biochem Behav 24:1479–1485PubMedGoogle Scholar
  10. Handley SL, Mithani S (1984) Effects of α-adrenoceptor agonists and antagonists in a maze-exploration model of ‘fear-motivated’ behaviour. Naunyn-Schmiedeberg's Arch Pharmacol 327:1–5Google Scholar
  11. Hjorth S, Carlsson A (1986) Is pindolol a mixed agonist-antagonist at central serotonin (5-HT) receptors? Eur J Pharmacol 129:131–138Google Scholar
  12. Hutson PH, Dourish CT, Curzon G (1986) Neurochemical and behavioural evidence for mediation of the hyperphagic action of 8-OH-DPAT by 5-HT cell body autoreceptors. Eur J Pharmacol 129:347–352Google Scholar
  13. Janssen PAJ (1985) The pharmacology of potent and selective S2-serotonergic antagonists. J Cardiovasc Pharmacol [Suppl 7] 7:S2-S11Google Scholar
  14. Johnston AL, File SE (1986) 5-HT and anxiety: promises and pitfalls. Pharmacol Biochem Behav 24:1467–1470Google Scholar
  15. Leysen JE, Awouters F, Kennis L, Laduron PM, Vaneberk PAJ (1981) Receptor profile of R41468 (ketanserin) a novel antagonist at 5-HT2 receptors. Life Sci 28:1015–1022Google Scholar
  16. Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PFM, Laduron PM (1985) Receptor binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27:600–611Google Scholar
  17. Middlemiss DN, Blakeborough L, Leather SR (1977) Direct evidence for an interaction of β-adrenergic blockers with the 5-HT receptor. Nature 267:289Google Scholar
  18. Montgomery KC (1955) The relation between fear induced by novel stimulation and exploratory behaviour. J Comp Physiol Psychol 48:254–260Google Scholar
  19. Nahorski SR, Wilcocks AL (1983) Interactions of β-adrenoceptor antagonists with 5-hydroxytryptamine receptor subtypes in rat cerebral cortex. Br J Pharmacol 78:107PGoogle Scholar
  20. Pedigo NW, Yamamura HI, Nelson DL (1981) Discrimination of multiple [3H]-5-Hydroxytryptamine binding sites by the neuroleptic spiperone in the rat brain. J Neurochem 36:220Google Scholar
  21. Pellow S, File SE (1986) Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze. A novel test of anxiety in the rat. Pharmacol Biochem Behav 24:525–529CrossRefPubMedGoogle Scholar
  22. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149–167Google Scholar
  23. Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: Differential binding of [3H]-5-HT, [3H]-LSD and [3H]-spiroperidol. Mol Pharmacol 16:687–699PubMedGoogle Scholar
  24. Richardson BP, Engel G (1986) The pharmacology and function of 5-HT3 receptors. Trends Neurol Sci 9:424Google Scholar
  25. Shephard RA, Buxton DA, Broadhurst PL (1982) Drug interactions do not support reduction of serotonin turnover as a mechanism of action of benzodiazepines. Neuropharmacology 21:1027Google Scholar
  26. Soubrié P (1986) Neurones sérotoninergiques et comportement. J Pharmacol 17:107–112Google Scholar
  27. Thiébot MH (1986) Are serotonergic neurones involved in the control of anxiety and in the anxiolytic activity of benzodiazepines? Pharmacol Biochem Behav 24:1471–1477Google Scholar
  28. Tricklebank MD (1985) The behavioural response to 5-HT receptor agonists and subtypes of the central 5-HT receptor. TIPS 6:403–407Google Scholar
  29. Tricklebank MD, Forler C, Fozard JR (1985) The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol 106:271–282Google Scholar
  30. Tricklebank MD, Middlemiss DN, Neill J (1986) Pharmacological analysis of the behavioural and thermoregulatory effects of the putative 5-HT1 receptor agonist, RU 24969 in the rat. Neuropharmacology 25:877–886Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • M. A. E. Critchley
    • 1
  • S. L. Handley
    • 1
  1. 1.Drug Mechanisms Research Group, Pharmaceutical Sciences InstituteAston UniversityBirminghamUK

Personalised recommendations